The emergence of targeted drugs such as cetuximab has greatly reduced drug toxicity and improved the effectiveness of CRC therapy, but the frequent gene mutations such as P53 and KRAS in CRC cells always lead to clinical resistance to targeted drugs.7 The gene discussed is KRAS; the disease is colorectal carcinoma.